Bausch Health (BHC) has rejected recent debt-restructuring proposals from bondholders as it weighs a sale of its Bausch + Lomb vision care business that could bring in billions of dollars to pay creditors and rewards investors, the Wall Street Journal’s Soma Biswas reports, citing people familiar with the matter. The company turned down proposals by a group of bondholders including Apollo Global (APO) and GoldenTree that sought to restructure debt without filing for bankruptcy, the author notes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Galecto announces the appointment of Wechsler to its Board of Directors
- M&A News: TPG and Blackstone Could Eye Joint Bid for Bausch + Lomb (NYSE:BLCO)
- TPG, Blackstone teaming for Bausch + Lomb bid, may be up to $25/share, FT says
- Bausch Health call volume above normal and directionally bullish
- Bausch Health rises 10.1%